Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone

Daniela Merlotti, Domenico Rendina, Luigi Gennari, Giuseppe Mossetti, Fernando Gianfrancesco, Giuseppe Martini, Gianpaolo De Filippo, Annalisa Avanzati, Beatrice Franci, Maria Stella Campagna, Pasquale Strazzullo, Ranuccio Nuti

Research output: Contribution to journalArticle

Abstract

Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4mg) or neridronate (200mg) given as a single intravenous infusion showed a similar short-term efficacy in achieving biochemical remission in up to 90% of patient nonresponders to pamidronate. In this study we compared the long-term (36 months) effects of a same neridronate dose (200mg) given as an intravenous (100-mg infusion for 2 consecutive days) or intramuscular (25-mg injection weekly for 2 months) regimen in 56 patients with active PDB. All patients were advised to receive calcium plus vitamin D supplementation throughout the study period. At 6 months, 92.6% and 96.5% of patients receiving intravenous and intramuscular neridronate, respectively, achieved a therapeutic response [defined as normalization of alkaline phosphatase (ALP) levels or a reduction of at least 75% in total ALP excess]. The response to treatment was significantly correlated with baseline ALP and 25-hydroxyvitamin D [25(OH)D] levels at 6 months. The decrease in ALP levels was highest in patients with higher baseline total or bone-specific ALP levels and with higher 25(OH)D levels at 6 months. Response rates were maintained at 12 months but decreased progressively at 24 and 36 months without significant differences between the two neridronate regimens. Both regimens were well tolerated. The only relevant side effect was an acute-phase response occurring in 14% of the patients. In conclusion, these results indicate that a 200-mg intramuscular neridronate course has a similar efficacy as an intravenous infusion of the same dose for the treatment of PDB and might be of particular value for patients intolerant to oral bisphosphonates and unwilling or unable to undergo intravenous infusions. © 2011 American Society for Bone and Mineral Research.

Original languageEnglish
Pages (from-to)512-518
Number of pages7
JournalJournal of Bone and Mineral Research
Volume26
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Osteitis Deformans
Alkaline Phosphatase
Intravenous Infusions
zoledronic acid
pamidronate
Therapeutics
Acute-Phase Reaction
Diphosphonates
6-amino-1-hydroxyhexane-1,1-diphosphonate
Vitamin D
Calcium
Bone and Bones
Injections

Keywords

  • bisphosphonates
  • intramuscular regimen
  • intravenous regimen
  • neridronate
  • Paget disease of bone

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Merlotti, D., Rendina, D., Gennari, L., Mossetti, G., Gianfrancesco, F., Martini, G., ... Nuti, R. (2011). Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone. Journal of Bone and Mineral Research, 26(3), 512-518. https://doi.org/10.1002/jbmr.237

Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone. / Merlotti, Daniela; Rendina, Domenico; Gennari, Luigi; Mossetti, Giuseppe; Gianfrancesco, Fernando; Martini, Giuseppe; De Filippo, Gianpaolo; Avanzati, Annalisa; Franci, Beatrice; Campagna, Maria Stella; Strazzullo, Pasquale; Nuti, Ranuccio.

In: Journal of Bone and Mineral Research, Vol. 26, No. 3, 03.2011, p. 512-518.

Research output: Contribution to journalArticle

Merlotti, D, Rendina, D, Gennari, L, Mossetti, G, Gianfrancesco, F, Martini, G, De Filippo, G, Avanzati, A, Franci, B, Campagna, MS, Strazzullo, P & Nuti, R 2011, 'Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone', Journal of Bone and Mineral Research, vol. 26, no. 3, pp. 512-518. https://doi.org/10.1002/jbmr.237
Merlotti, Daniela ; Rendina, Domenico ; Gennari, Luigi ; Mossetti, Giuseppe ; Gianfrancesco, Fernando ; Martini, Giuseppe ; De Filippo, Gianpaolo ; Avanzati, Annalisa ; Franci, Beatrice ; Campagna, Maria Stella ; Strazzullo, Pasquale ; Nuti, Ranuccio. / Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone. In: Journal of Bone and Mineral Research. 2011 ; Vol. 26, No. 3. pp. 512-518.
@article{cf6e053d0d0a4a3894823af759af386e,
title = "Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone",
abstract = "Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4mg) or neridronate (200mg) given as a single intravenous infusion showed a similar short-term efficacy in achieving biochemical remission in up to 90{\%} of patient nonresponders to pamidronate. In this study we compared the long-term (36 months) effects of a same neridronate dose (200mg) given as an intravenous (100-mg infusion for 2 consecutive days) or intramuscular (25-mg injection weekly for 2 months) regimen in 56 patients with active PDB. All patients were advised to receive calcium plus vitamin D supplementation throughout the study period. At 6 months, 92.6{\%} and 96.5{\%} of patients receiving intravenous and intramuscular neridronate, respectively, achieved a therapeutic response [defined as normalization of alkaline phosphatase (ALP) levels or a reduction of at least 75{\%} in total ALP excess]. The response to treatment was significantly correlated with baseline ALP and 25-hydroxyvitamin D [25(OH)D] levels at 6 months. The decrease in ALP levels was highest in patients with higher baseline total or bone-specific ALP levels and with higher 25(OH)D levels at 6 months. Response rates were maintained at 12 months but decreased progressively at 24 and 36 months without significant differences between the two neridronate regimens. Both regimens were well tolerated. The only relevant side effect was an acute-phase response occurring in 14{\%} of the patients. In conclusion, these results indicate that a 200-mg intramuscular neridronate course has a similar efficacy as an intravenous infusion of the same dose for the treatment of PDB and might be of particular value for patients intolerant to oral bisphosphonates and unwilling or unable to undergo intravenous infusions. {\circledC} 2011 American Society for Bone and Mineral Research.",
keywords = "bisphosphonates, intramuscular regimen, intravenous regimen, neridronate, Paget disease of bone",
author = "Daniela Merlotti and Domenico Rendina and Luigi Gennari and Giuseppe Mossetti and Fernando Gianfrancesco and Giuseppe Martini and {De Filippo}, Gianpaolo and Annalisa Avanzati and Beatrice Franci and Campagna, {Maria Stella} and Pasquale Strazzullo and Ranuccio Nuti",
year = "2011",
month = "3",
doi = "10.1002/jbmr.237",
language = "English",
volume = "26",
pages = "512--518",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone

AU - Merlotti, Daniela

AU - Rendina, Domenico

AU - Gennari, Luigi

AU - Mossetti, Giuseppe

AU - Gianfrancesco, Fernando

AU - Martini, Giuseppe

AU - De Filippo, Gianpaolo

AU - Avanzati, Annalisa

AU - Franci, Beatrice

AU - Campagna, Maria Stella

AU - Strazzullo, Pasquale

AU - Nuti, Ranuccio

PY - 2011/3

Y1 - 2011/3

N2 - Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4mg) or neridronate (200mg) given as a single intravenous infusion showed a similar short-term efficacy in achieving biochemical remission in up to 90% of patient nonresponders to pamidronate. In this study we compared the long-term (36 months) effects of a same neridronate dose (200mg) given as an intravenous (100-mg infusion for 2 consecutive days) or intramuscular (25-mg injection weekly for 2 months) regimen in 56 patients with active PDB. All patients were advised to receive calcium plus vitamin D supplementation throughout the study period. At 6 months, 92.6% and 96.5% of patients receiving intravenous and intramuscular neridronate, respectively, achieved a therapeutic response [defined as normalization of alkaline phosphatase (ALP) levels or a reduction of at least 75% in total ALP excess]. The response to treatment was significantly correlated with baseline ALP and 25-hydroxyvitamin D [25(OH)D] levels at 6 months. The decrease in ALP levels was highest in patients with higher baseline total or bone-specific ALP levels and with higher 25(OH)D levels at 6 months. Response rates were maintained at 12 months but decreased progressively at 24 and 36 months without significant differences between the two neridronate regimens. Both regimens were well tolerated. The only relevant side effect was an acute-phase response occurring in 14% of the patients. In conclusion, these results indicate that a 200-mg intramuscular neridronate course has a similar efficacy as an intravenous infusion of the same dose for the treatment of PDB and might be of particular value for patients intolerant to oral bisphosphonates and unwilling or unable to undergo intravenous infusions. © 2011 American Society for Bone and Mineral Research.

AB - Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4mg) or neridronate (200mg) given as a single intravenous infusion showed a similar short-term efficacy in achieving biochemical remission in up to 90% of patient nonresponders to pamidronate. In this study we compared the long-term (36 months) effects of a same neridronate dose (200mg) given as an intravenous (100-mg infusion for 2 consecutive days) or intramuscular (25-mg injection weekly for 2 months) regimen in 56 patients with active PDB. All patients were advised to receive calcium plus vitamin D supplementation throughout the study period. At 6 months, 92.6% and 96.5% of patients receiving intravenous and intramuscular neridronate, respectively, achieved a therapeutic response [defined as normalization of alkaline phosphatase (ALP) levels or a reduction of at least 75% in total ALP excess]. The response to treatment was significantly correlated with baseline ALP and 25-hydroxyvitamin D [25(OH)D] levels at 6 months. The decrease in ALP levels was highest in patients with higher baseline total or bone-specific ALP levels and with higher 25(OH)D levels at 6 months. Response rates were maintained at 12 months but decreased progressively at 24 and 36 months without significant differences between the two neridronate regimens. Both regimens were well tolerated. The only relevant side effect was an acute-phase response occurring in 14% of the patients. In conclusion, these results indicate that a 200-mg intramuscular neridronate course has a similar efficacy as an intravenous infusion of the same dose for the treatment of PDB and might be of particular value for patients intolerant to oral bisphosphonates and unwilling or unable to undergo intravenous infusions. © 2011 American Society for Bone and Mineral Research.

KW - bisphosphonates

KW - intramuscular regimen

KW - intravenous regimen

KW - neridronate

KW - Paget disease of bone

UR - http://www.scopus.com/inward/record.url?scp=79951829302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951829302&partnerID=8YFLogxK

U2 - 10.1002/jbmr.237

DO - 10.1002/jbmr.237

M3 - Article

C2 - 20814970

AN - SCOPUS:79951829302

VL - 26

SP - 512

EP - 518

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -